 |
||||||||||||||
|
||||||||||||||
FOR IMMEDIATE RELEASE Jefferies Expands Healthcare Focus to Biotechnology; Adam Walsh, MD, Joins Equity Research Team NEW YORK, Mar 5, 2002 (BUSINESS WIRE) -- Jefferies & Company, Inc., the principal operating subsidiary of Jefferies Group, Inc. (NYSE: JEF), today announced that Adam Anderson Walsh, MD, has joined the firm as a Vice President and Senior Equity Research Analyst in Biotechnology and Specialty Pharmaceuticals. Dr. Walsh will be based in the firm's San Francisco office and will report to Steven R. Black, Director of Equity Research. "Adam Walsh is a perfect complement to Jefferies' healthcare research effort," commented Richard B. Handler, Chairman and CEO of Jefferies. "We continue to enhance our integrated research platform to focus on strategic opportunities." "Dr. Walsh's medical degree and his understanding of the life sciences are fundamental to quality biotech research," added John C. Shaw, Jr., President of Jefferies. "His experience definitely adds value for our investor base." "I am pleased to join Jefferies' outstanding healthcare research team and look forward to leveraging my medical background and clinical contacts to build a premier biotechnology research product," said Dr. Walsh. "A dramatic increase in the number of identified drug targets, an aging population, and a full and maturing biotechnology pipeline will create a robust environment for knowledgeable investors over the next decade." Dr. Walsh's focus on biotechnology is a key addition to Jefferies' overall healthcare strategy. The firm's healthcare research team also includes: David K. Francis, Healthcare Information Technology; Andrew L. May, Specialty Healthcare Services; Frank G. Morgan, Acute-Care Hospitals, Facility-Based Healthcare Services; David H. Windley, CFA, CPA, Pharmaceutical Services, Pharmaceutical IT; Nicholas C. Turner, Ph.D., European Biotechnology and Pharmaceuticals; and Eliezer J. ("Elie") Radinsky, High Yield Healthcare Research. Prior to Jefferies, Dr. Walsh spent two years as a Specialty Pharmaceuticals analyst at Thomas Weisel Partners. He also received invaluable experience as a practicing physician during the two years prior. Dr. Walsh received his MD and MBA from Tufts University in 1999 and a BS in Business Administration and a BA in Psychology from the University of Colorado, Boulder in 1993. About Jefferies Jefferies & Company, Inc. is an institutional brokerage firm and an investment bank. The firm provides outstanding trading execution in equity, high yield, convertible and international securities as well as fundamental research for institutional investors. As an investment bank, Jefferies offers capital raising, mergers and acquisitions, and restructuring services for middle market companies. The firm also provides prime brokerage and securities lending services. Jefferies' leadership in equity trading is recognized by numerous consulting and survey organizations. Jefferies Group, Inc. employs more than 1,200 people in 20 offices worldwide, including Atlanta, Boston, Chicago, Dallas, Hong Kong, London, Los Angeles, New York, Paris, San Francisco, Tokyo and Zurich. Further information about Jefferies, including a description of trading, research and investment banking services, can be found at www.jefco.com. CONTACT: |
||||||||||||||
| Site Map | Customer Notices and Policies | Contact Us | ||
| © 2008 Jefferies & Company, Inc. | Member, SIPC |